Cargando…

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial

INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiahui, Kong, Weili, Hu, Pingzhao, Jonker, Derek, Moore, Malcolm, Ringash, Jolie, Shapiro, Jeremy, Zalcberg, John, Simes, John, Tu, Dongsheng, O'Callaghan, Chris J., Liu, Geoffrey, Xu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028035/
https://www.ncbi.nlm.nih.gov/pubmed/36281472
http://dx.doi.org/10.1002/cam4.5341
_version_ 1784909848949817344
author Zhang, Jiahui
Kong, Weili
Hu, Pingzhao
Jonker, Derek
Moore, Malcolm
Ringash, Jolie
Shapiro, Jeremy
Zalcberg, John
Simes, John
Tu, Dongsheng
O'Callaghan, Chris J.
Liu, Geoffrey
Xu, Wei
author_facet Zhang, Jiahui
Kong, Weili
Hu, Pingzhao
Jonker, Derek
Moore, Malcolm
Ringash, Jolie
Shapiro, Jeremy
Zalcberg, John
Simes, John
Tu, Dongsheng
O'Callaghan, Chris J.
Liu, Geoffrey
Xu, Wei
author_sort Zhang, Jiahui
collection PubMed
description INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations (“patient clusters”) in the CO.20 clinical trial longitudinal QoL data. Classes were then evaluated for differences in clinico‐epidemiologic characteristics and overall survival (OS). METHODS AND MATERIALS: In CO.20, 750 chemotherapy‐refractory metastatic colorectal cancer (CRC) patients were randomized to receive Brivanib+Cetuximab (n = 376, experimental arm) versus Cetuximab+Placebo (n = 374, standard arm) for 16 weeks. EORTC‐QLQ‐C30 QoL summary scores were calculated for each patient at seven time points, and GMM was applied to identify patient clusters (termed “classes”). Log‐rank/Kaplan–Meier and multivariable Cox regression analyses were conducted to analyze the survival performance between classes. Cox analyses were used to explore the relationship between baseline QoL, individual slope, and the quadratic terms from the GMM output with OS. RESULTS: In univariable analysis, the linear mixed effect model (LMM) identified sex and ECOG Performance Status as strongly associated with the longitudinal QoL score (p < 0.01). The patients within each treatment arm were clustered into three distinct QoL‐based classes by GMM, respectively. The three classes identified in the experimental (log‐rank p‐value = 0.00058) and in the control arms (p < 0.0001) each showed significantly different survival performance. The GMM's baseline, slope, and quadratic terms were each significantly associated with OS (p < 0.001). CONCLUSION: GMM can be used to analyze longitudinal QoL data in cancer studies, by identifying unobserved subpopulations (patient clusters). As demonstrated by CO.20 data, these classes can have important implications, including clinical prognostication.
format Online
Article
Text
id pubmed-10028035
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100280352023-03-22 Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial Zhang, Jiahui Kong, Weili Hu, Pingzhao Jonker, Derek Moore, Malcolm Ringash, Jolie Shapiro, Jeremy Zalcberg, John Simes, John Tu, Dongsheng O'Callaghan, Chris J. Liu, Geoffrey Xu, Wei Cancer Med RESEARCH ARTICLES INTRODUCTION: Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations (“patient clusters”) in the CO.20 clinical trial longitudinal QoL data. Classes were then evaluated for differences in clinico‐epidemiologic characteristics and overall survival (OS). METHODS AND MATERIALS: In CO.20, 750 chemotherapy‐refractory metastatic colorectal cancer (CRC) patients were randomized to receive Brivanib+Cetuximab (n = 376, experimental arm) versus Cetuximab+Placebo (n = 374, standard arm) for 16 weeks. EORTC‐QLQ‐C30 QoL summary scores were calculated for each patient at seven time points, and GMM was applied to identify patient clusters (termed “classes”). Log‐rank/Kaplan–Meier and multivariable Cox regression analyses were conducted to analyze the survival performance between classes. Cox analyses were used to explore the relationship between baseline QoL, individual slope, and the quadratic terms from the GMM output with OS. RESULTS: In univariable analysis, the linear mixed effect model (LMM) identified sex and ECOG Performance Status as strongly associated with the longitudinal QoL score (p < 0.01). The patients within each treatment arm were clustered into three distinct QoL‐based classes by GMM, respectively. The three classes identified in the experimental (log‐rank p‐value = 0.00058) and in the control arms (p < 0.0001) each showed significantly different survival performance. The GMM's baseline, slope, and quadratic terms were each significantly associated with OS (p < 0.001). CONCLUSION: GMM can be used to analyze longitudinal QoL data in cancer studies, by identifying unobserved subpopulations (patient clusters). As demonstrated by CO.20 data, these classes can have important implications, including clinical prognostication. John Wiley and Sons Inc. 2022-10-24 /pmc/articles/PMC10028035/ /pubmed/36281472 http://dx.doi.org/10.1002/cam4.5341 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Zhang, Jiahui
Kong, Weili
Hu, Pingzhao
Jonker, Derek
Moore, Malcolm
Ringash, Jolie
Shapiro, Jeremy
Zalcberg, John
Simes, John
Tu, Dongsheng
O'Callaghan, Chris J.
Liu, Geoffrey
Xu, Wei
Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
title Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
title_full Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
title_fullStr Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
title_full_unstemmed Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
title_short Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
title_sort clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: implementation on cctg/agitg co.20 trial
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028035/
https://www.ncbi.nlm.nih.gov/pubmed/36281472
http://dx.doi.org/10.1002/cam4.5341
work_keys_str_mv AT zhangjiahui clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT kongweili clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT hupingzhao clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT jonkerderek clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT mooremalcolm clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT ringashjolie clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT shapirojeremy clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT zalcbergjohn clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT simesjohn clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT tudongsheng clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT ocallaghanchrisj clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT liugeoffrey clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial
AT xuwei clusteringonlongitudinalqualityoflifemeasurementsusinggrowthmixturemodelsforclinicalprognosisimplementationoncctgagitgco20trial